Clinical Trials

A very large pragmatic trial that will examine the effects of statins on dementia prevention in the elderly. The first statin trial with a non-CVD primary outcome - survival free of dementia or persisting disability. Using a placebo-controlled pragmatic clinical trial (PCT) design across PCORnet and Veterans Affairs health care systems, we will evaluate the risks and benefits of a moderate-intensity statin on important health outcomes for older adults.

MC - Chippewa Falls Center

2655 CTY HWY I

CHIPPEWA FALLS, WI 54729

MC - Wausau Center

2727 PLAZA DRIVE

WAUSAU, WI 54401

MC - Wisconsin Rapids Center

220 24TH ST SOUTH

WISCONSIN RAPIDS, WI 54494

MMC - Dickinson

1721 S Stephenson Ave

Iron Mountain, MI 49801

MMC - Eau Claire Cancer Center

2200 Craig Road

Eau Claire, WI 54701

MMC - Ladysmith

1200 Port Arthur Rd

Ladysmith, WI 54848

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

MMC - Minocqua

9576 WI-70 Trunk

MINOCQUA, WI 54548

MMC - Neillsville

N3708 River Ave

Neillsville, Wisconsin 54456

MMC - Rice Lake

1700 W Stout St

Rice Lake, WI 54868

MMC - Stevens Point Campus

4100 WI-66

Stevens Point, WI 54482

MMC - Weston

3400 Ministry Parkway

Weston, WI 54476

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with some genetic changes or abnormalities (mutations) may benefit from treatment that targets that particular genetic mutation. ComboMATCH is designed to match patients to a treatment that may work to control their tumor and may help doctors plan better treatment for patients with locally advanced or advanced solid tumors.

MMC - Eau Claire Cancer Center

2200 Craig Road

Eau Claire, WI 54701

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

MMC - Minocqua

9576 WI-70 Trunk

MINOCQUA, WI 54548

MMC - Rice Lake

1700 W Stout St

Rice Lake, WI 54868

MMC - Stevens Point Campus

4100 WI-66

Stevens Point, WI 54482

MMC - Weston

3400 Ministry Parkway

Weston, WI 54476

This phase II ComboMATCH treatment trial compares the effect of neratinib to the combination of neratinib and palbociclib in treating patients with HER2 positive solid tumors. Neratinib and palbociclib are in a class of medications called kinase inhibitors. They work by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of tumor cells. Giving neratinib and palbociclib in combination may shrink or stabilize cancers that over-express a specific biomarker called HER2.

MMC - Eau Claire Cancer Center

2200 Craig Road

Eau Claire, WI 54701

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

MMC - Minocqua

9576 WI-70 Trunk

MINOCQUA, WI 54548

MMC - Rice Lake

1700 W Stout St

Rice Lake, WI 54868

MMC - Stevens Point Campus

4100 WI-66

Stevens Point, WI 54482

MMC - Weston

3400 Ministry Parkway

Weston, WI 54476

The primary objective of this study is to examine whether HBOT is an effective treatment for mTBI in concussed athletes by quantifying time of return to baseline in neurocognitive performance in HBOT treated versus untreated study participants. A secondary objective is to investigate associations between biomarkers and neurocognitive abnormalities in combat athletes with mTBI.

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

The purpose of the Clinical Registry Investigating Bardet-Biedl Syndrome (CRIBBS) is to establish and perpetuate an international registry enabling subject recruitment for clinical natural history studies, therapeutic trials and collection of biological specimens of blood and saliva specimens of affected individuals and family members with a rare disorder, Bardet-Biedl syndrom (BBS). Biological specimens will be collected for future clinical studies, as well as other studies to examine the relationship between genetic mutations and clinical features. Specimens will be stored in the Core Laboratory.

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

Managed Access Program (MAP) Cohort Treatment Plan to Provide Access to IFx-Hu2.0 for Patients with Progressive Metastatic Merkel Cell Carcinoma

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (S1400). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes a non-match sub-study which will include all screened patients not eligible for any of the biomarker-driven sub-studies. This sub-study will compare a non-match therapy to standard of care also with the goal of approval.

Marshfield Medical Center - Rice Lake

1700 W STOUT ST

RICE LAKE, WI 54868

MC - Chippewa Falls Center

2655 CTY HWY I

CHIPPEWA FALLS, WI 54729

MC - Wausau Center

2727 PLAZA DRIVE

WAUSAU, WI 54401

MC - Wisconsin Rapids Center

220 24TH ST SOUTH

WISCONSIN RAPIDS, WI 54494

MMC - Eau Claire Cancer Center

2200 Craig Road

Eau Claire, WI 54701

MMC - Ladysmith

1200 Port Arthur Rd

Ladysmith, WI 54848

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

MMC - Minocqua

9576 WI-70 Trunk

MINOCQUA, WI 54548

MMC - Stevens Point Campus

4100 WI-66

Stevens Point, WI 54482

MMC - Weston

3400 Ministry Parkway

Weston, WI 54476

Memory disorders and dementias are a leading cause of aging related death and disability. As a part of the mission of Marshfield Clinic to provide cutting edge care to our communities, we are aiming to create a center of excellence for diagnosis and care of dementias through the newly consolidated Memory Disorders Cognitive Neurology Division (MDCN). 1. Establish the Marshfield Neuropathology Core as an Integral part of the Memory Disorders Division by providing the “gold standard” validation of the clinical diagnosis and imaging surrogates through neuropathological examination of patients who come to autopsy. 2. Establish a clinical database to track neuropathology cases and allow clinical research use.

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

This phase II trial studies how well TPIV100 and sargramostim work in treating patients with HER2 positive, stage II-III breast cancer that has remained after chemotherapy and surgery. It also studies why some HER2 positive breast cancer patients respond better to chemotherapy in combination with trastuzumab and pertuzumab. TPIV100 is a type of vaccine made from HER2 peptide that may help the body build an effective immune response to kill tumor cells that express HER2. Sargramostim increases the number of white blood cells in the body following chemotherapy for certain types of cancer and is used to alert the immune system. It is not yet known if TPIV100 and sargramostim will work better in treating patients with HER2 positive, stage II-III breast cancer.

MMC - Eau Claire Cancer Center

2200 Craig Road

Eau Claire, WI 54701

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

MMC - Minocqua

9576 WI-70 Trunk

MINOCQUA, WI 54548

MMC - Rice Lake

1700 W Stout St

Rice Lake, WI 54868

MMC - Stevens Point Campus

4100 WI-66

Stevens Point, WI 54482

MMC - Weston

3400 Ministry Parkway

Weston, WI 54476

The Heartland Study is a prospective, observational study that will enroll up to 2,600 pregnant participants across the Heartland States in the U.S. The objective of the Heartland Study is to address major knowledge gaps concerning the health effects of herbicides on maternal and infant health. The study is being conducted to evaluate the associations between environmental exposures to herbicides during and after pregnancy and reproductive health outcomes. The study is measuring multiple biomarkers of herbicide exposure among pregnant Midwesterners and their partners to evaluate associations with pregnancy and childbirth outcomes, epigenetic biomarkers of exposure, and child development.

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449